The personalized cancer vaccine market size was valued at USD 208.37 million in 2024 and is expected to reach USD 4040.50 million by 2032, growing at a CAGR of 44.88% over 2025-2032.
The personalized cancer vaccines market is seeing robust growth on the back of genomic, immunotherapy, and artificial intelligence advances. Cancer is a leading cause of death globally, and there is a growing demand for treatment that is both specific and efficient. Individualized cancer vaccines, tailored to the unique genetic profile of a patient's tumor, are more effective and have fewer side effects. This need had fueled a new wave of R&D, notably in the area of mRNA platforms and neoantigen identification.
Modern, BioNTech, and Gritstone Bio are among the companies in the vanguard, using mRNA and AI tools to speed the pace of vaccine development. Moderna and Merck’s mRNA-4157/V940 vaccine for melanoma is in late-phase clinical trials already. Regulators, such as the FDA and EMA, are also providing fast-track approvals and funding support to the sector. The U.S., Germany, and China are issuing grant-and-tax incentives to drive innovations effectively, which is favorable for personalized cancer vaccine market growth.
A large-scale Phase 3 trial of mRNA-4157/V940 for non-small cell lung cancer was initiated in April 2025 by Moderna and Merck, indicating its usage for the treatment of diseases beyond melanoma.
Furthermore, the supply side is in rapid flux, with growing partnerships between drug companies and academic research institutions. For instance, BioNTech has recently developed a relationship with the U.K. to provide up to 10,000 individualized cancer immunotherapies by 2030, demonstrating increased international trust in this course of treatment. Meanwhile, growing patients' and oncologists' awareness related to the advantages of personalized immunotherapy is contributing to the rise in the adoption of these therapies. The availability of high-throughput sequencing technologies has further facilitated the development of personalized vaccines for other patients more rapidly and affordably.
Investment in R&D has rocketed, with BioNTech revealing a USD 1.16 billion commitment by 2025 to broaden its personalized vaccine ability. These developments, in addition to supportive government policies, increasing healthcare facilities in developing nations, and rising cases of cancers such as lung, melanoma, and pancreatic, are likely to continue to drive the personalized cancer vaccine market trends over the coming years.
In March 2025, Germany’s BioNTech announced a USD 1.16 billion investment to expand R&D and manufacturing for personalized cancer vaccines in Germany to support its lead in the personalized cancer vaccine market analysis.
Market Dynamics:
Drivers:
Rising Demand for Precision Medicine, Innovation in Vaccine Platforms, and Regulatory Support Fueling Growth
Personalized cancer vaccine market driving factors include a surge in demand for personalized medicine, technological development in genomics, and focused R&D investment. With the advent of personalized medicine, corporations are increasingly using NGS and bioinformatics to identify mutations present in tumor tissue, as cancer therapy becomes more and more target-specific. More companies, including Gritstone Bio and Genentech, are also working on AI-aided neoantigen vaccine design. Investment in R&D has continued to increase, and in 2024, Gritstone spent more than USD 120 million on the development of its oncology pipeline.
New regulatory policies also facilitate the global personalized cancer vaccine market. The FDA’s guidance in 2024 for personal therapeutic products focused on pathways for early-stage personalized vaccines that would yield fast approvals for the clinic. Furthermore, the expanding access to high-throughput sequencers and the progress in mRNA technologies are driving the scale of production of vaccines. The increasing size of the personalized cancer vaccine market is also being supported by immuno-oncology awareness campaigns and patient-focused drug development initiatives. These advancements and favorable regulations are collectively expanding the personalized cancer vaccine market size and will be responsible for long-term personalized cancer vaccine market growth.
Restraints:
High Production Costs, Complex Manufacturing, and Data Privacy Concerns Hindering Market Expansion
Although the personalized cancer vaccine market is highly promising, there are also significant restraints to the development and application of customized cancer vaccines that could limit their scalability. One of the major obstacles is the expense and intricate production of customized vaccines. Personalized cancer vaccines need to be personalized-designed for each patient, sequenced, and manufactured, making cost-effective and routine commercial levels of production logistics unfeasible. They can cost between USD 60,000 and USD 100,000 per patient to produce, which can restrict access and reimbursement in many markets. In addition, the time from biopsy to vaccine treatment can take weeks, a barrier for late-stage cancer patients.
Supply chain bottlenecks (the number of GMP-certified facilities and/or workforce proficiency) also impact the scalability of manufacturing. Furthermore, dependence on highly aggregated genomic data brings the issues of ethicality and privacy, particularly under GDPR and HIPAA legislations. In 2024, the co-investigation of the U.S. and EU regulatory agencies brought up the requirement for stricter governance of genomic data involved in cancer immunotherapy trials. All these considerations form an important bottleneck in the personalized cancer vaccine market analysis, influencing both patient adherence and investor trust. These barriers will keep limiting the personalized cancer vaccine market throughout the forecast period.
By Type
The dendritic cell vaccine segment dominated the market in 2024, owing to its superior clinical performance and significant history in antigen presentation for producing a better immune response. These vaccines are frequently patient-derived, autologous, and have demonstrated efficacy when used for the treatment of prostate cancer and glioblastoma. Their success is based on clinical evidence and trials that are continuing across various cancers.
On the other hand, the mRNA vaccine segment is the most rapidly growing one because of the fast development timelines, the flexible manufacturing process, and scalability. It is the kind of highly precise individualized therapy that mRNA vaccines, such as those being developed by Moderna and BioNTech, could make possible. Patient-specific neoantigens can be encoded into cVLPs, making them amenable to the next-gen personalized cancer vaccine market expansion.
By Technology
Cell-based vaccine technology, which has proven mechanisms with dendritic cells and tumor lysates, resulting in better immune responses, dominated the market share in 2024. Such therapies are already in extensive use in the experimental and approved settings of forms of solid and hematologic tumors. Their systematics are affected by their own infrastructure and clinical use for personalized cancer vaccine market trends.
The mRNA PCV segment is the most rapidly growing technology segment, mainly due to its ability to improve immunogenicity and the potential for easy modification. Backed by cutting-edge delivery technology and AI-powered antigen mapping, mRNA PCVs are revolutionizing vaccine discovery and getting universities’ and pharma companies’ personalized cancer therapies from bench to bedside faster than conventional platforms.
By Distribution Channel
Hospital dominated the global personalized cancer vaccine market in 2024 with a 59.02% share, owing to their central position in the ecosystem of advanced cancer treatment, clinical research setup, and availability of genomic diagnostic tools. The majority of immunotherapy delivery is also via hospitals, particularly in the U.S., Germany, and Japan, where integrated care models and research partnerships exist.
The clinics sector is anticipated to be the most rapidly growing in the coming years due to the availability of personalized treatments in the outpatient department, as well as the decentralization of cancer care. As genomic testing and vaccine manufacturing become increasingly accessible and cost-effective, clinics are better-prepared to offer personalized immunotherapies, enabling the increasing availability of personalized cancer vaccines to the wider population.
North America led the global personalized cancer vaccine market, with a contribution of 34.10% to the market share in 2024, owing to the strong biotech landscape, ICI being way ahead, and the investment in cancer research being massive.
The U.S. personalized cancer vaccine market size was valued at USD 53.69 million in 2024 and is expected to reach USD 935.15 million by 2032, growing at a CAGR of 42.99% over 2025-2032. The U.S. is the dominant regional player as it has a high level of clinical trial activities and government funding; in 2024, the National Cancer Institute (NCI) budgeted for a cancer-related R&D spending of more than USD 7.2 billion. Key companies, such as Moderna, Gritstone Bio, and NantKwest, are conducting late-stage trials in the U.S., hastening clinical development. Canada is now positioning itself as a regional AI-drug discovery and vaccine hub, due to supportive regulatory conditions and academic-industry partnerships. Progress is slowly occurring in Mexico through public-private partnerships and in infrastructure for genomic medicine.
The personalized cancer vaccine market in Europe is growing at a good pace, owing to favorable regulations coupled with collaborative research groups and cancer genomics projects. Germany and the U.K. are the ones who are pioneering the innovation. Germany, where BioNTech is based, is a top player, with more than €1 billion (~USD 1.16 billion) invested in personalized vaccines in 2025 alone.
The U.K. plans to treat around 10,000 patients with personalized immune therapies by 2030 as part of a BioNTech-backed effort. The area derives support from the European Union’s Horizon Europe program, which earmarked USD 1.45 billion for cancer research in 2024. France and Italy are strengthening infrastructure via a national precision medicine programme. Collaborative support by EMA for accelerated approvals is also augmenting the regional personalized cancer vaccine market share.
The Asia Pacific personalized cancer vaccine market is projected to be the fastest-growing, owing to the increasing incidence of cancer, growing healthcare infrastructure, and rising investment in genomics research. China is also outpacing the rest of the region with its national precision medicine initiative and fast-growing biotech sector, which drew more than USD 10 billion of investment in oncology in 2024.
Local Chinese companies, such as GeneCast and WuXi Biologics, are moving in on the personalized vaccine sector with domestic technology. Japan is prioritizing mRNA-based immunotherapies, buoyed by regulatory changes to fast-track regulatory approvals. India is beginning to act as a location for clinical trials, with cheaper costs and increased Indian government focus on personalized medicine. Australia and Singapore are betting on AI-based oncology research to become regional centers of clinical innovation. The growing penetration of genomic sequencing and the high cost of healthcare make Asia Pacific the most attractive region for the future of the personalized cancer vaccine market analysis.
Leading personalized cancer vaccine companies operating in the market include Gritstone Bio, Dendreon Pharmaceuticals, CureVac, NeoCura, Innovent, Stemirna Therapeutics, Elicio Therapeutics, Evaxion Biotech, Imugene, and Nouscom, driving innovation and development across the industry.
In May 2025, Evaxion confirmed dosing of the first patient in the one-year extension of its Phase 2 EVX‑01 trial targeting advanced melanoma. This extension is designed to assess long-term immune durability and monitor clinical outcomes up to three years.
In November 2024, Gritstone announced promising interim Phase 2 results for its GRANITE personalized neoantigen vaccine in microsatellite-stable colorectal cancer. The vaccine showed a 27% relative reduction in progression or death across all treated patients and 50% in those with low ctDNA levels, underscoring its potential clinical benefit.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 208.37 million |
| Market Size by 2032 | USD 4040.50 million |
| CAGR | CAGR of 44.88% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Dendritic Cell, RNA-Based (mRNA), Neoantigen-Based, and Tumor-Associated Antigen (TAA) Vaccines) • By Technology (Cell-based, mRNA PCV, and Others) • By Distribution Channel (Hospitals, Clinics, and Research & Academic Institutes) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Gritstone Bio, Dendreon Pharmaceuticals, CureVac, NeoCura, Innovent, Stemirna Therapeutics, Elicio Therapeutics, Evaxion Biotech, Imugene, and Nouscom |
Ans: The personalized cancer vaccine market size was valued at USD 208.37 million in 2024 and is expected to reach USD 4040.50 million by 2032, growing at a CAGR of 44.88% over 2025-2032.
Ans: The growth is driven by rising cancer prevalence, advancements in genomic technologies, increasing success in clinical trials, and strong investments from biotech firms and government bodies. Additionally, demand for precision medicine and immunotherapy is accelerating adoption.
Ans: Key players include Moderna, BioNTech, Gritstone Bio, CureVac, Nouscom, Imugene, Evaxion Biotech, Stemirna Therapeutics, Elicio Therapeutics, and NeoCura. These companies are actively developing mRNA- and neoantigen-based vaccine platforms.
Ans: North America, particularly the U.S., leads due to advanced biotech infrastructure, high R&D investment, and strong regulatory support. Europe and Asia-Pacific (notably China) are also emerging with increasing clinical activity and partnerships.
Ans: Future trends include the integration of AI in vaccine design, expansion to multiple cancer types, growing use of mRNA platforms, and an increase in combination therapies with checkpoint inhibitors. Commercialization is expected to surge as more late-stage candidates receive approvals.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Clinical Trial Landscape and Patient Enrollment Trends (2024)
5.2 Prevalence of Target Cancer Types (2024)
5.3 R&D Investment and Funding Trends (2021–2024)
5.4 Regulatory Approvals and Fast-Track Designations (2020–2024)
5.5 Manufacturing and Commercialization Capacity (2021–2032)
5.6 Healthcare Spending on Immunotherapy and Precision Cell-based (2024)
5.7 Prescription and Usage Trends of Companion Diagnostics (2024)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Personalized Cancer Vaccine Market Segmentation by Type
7.1 Chapter Overview
7.2 Dendritic Cell
7.2.1 Dendritic Cell Market Trends Analysis (2021-2032)
7.2.2 Dendritic Cell Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 RNA-Based (mRNA)
7.3.1 RNA-Based (mRNA) Market Trends Analysis (2021-2032)
7.3.2 RNA-Based (mRNA) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Neoantigen-Based
7.4.1 Neoantigen-Based Market Trends Analysis (2021-2032)
7.4.2 Neoantigen-Based Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Tumor-Associated Antigen (TAA) Vaccines
7.5.1 Tumor-Associated Antigen (TAA) Vaccines Market Trends Analysis (2021-2032)
7.5.2 Tumor-Associated Antigen (TAA) Vaccines Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Personalized Cancer Vaccine Market Segmentation By Technology
8.1 Chapter Overview
8.2 Cell-based
8.2.1 Cell-based Market Trend Analysis (2021-2032)
8.2.2 Cell-based Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 mRNA PCV
8.3.1 mRNA PCV Market Trends Analysis (2021-2032)
8.3.2 mRNA PCV Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Others
8.4.1 Others Market Trends Analysis (2021-2032)
8.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Personalized Cancer Vaccine Market Segmentation By Distribution Channel
9.1 Chapter Overview
9.2 Hospitals
9.2.1 Hospitals Market Trends Analysis (2021-2032)
9.2.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Clinics
9.3.1 Clinics Market Trends Analysis (2021-2032)
9.3.2 Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Research & Academic Institutes
9.4.1 Research & Academic Institutes Market Trends Analysis (2021-2032)
9.4.2 Research & Academic Institutes Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Personalized Cancer Vaccine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.2.4 North America Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.2.5 North America Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.2.6.2 USA Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.2.6.3 USA Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.2.7.2 Canada Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.2.7.3 Canada Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.2.8.2 Mexico Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.2.8.3 Mexico Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Personalized Cancer Vaccine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.4 Europe Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.5 Europe Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.6 Germany
10.3.1.6.1 Germany Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.1.6.2 Germany Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.1.6.3 Germany Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.7.2 France Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.7.3 France Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.8.2 UK Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.8.3 UK Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.9.2 Italy Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.9.3 Italy Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.10.2 Spain Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.10.3 Spain Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.12 Poland
10.3.12.1 Poland Personalized Cancer Vaccine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.12.1 Poland Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.12.3 Poland Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.12.3 Poland Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.13 Turkey
10.3.13.1 Turkey Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.13.2 Turkey Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.13.3 Turkey Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.14 Rest of Europe
10.3.14.1 Rest of Europe Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.14.2 Rest of Europe Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.14.3 Rest of Europe Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4 Asia-Pacific
10.4.1 Trends Analysis
10.4.2 Asia-Pacific Personalized Cancer Vaccine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia-Pacific Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.4 Asia-Pacific Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.4.5 Asia-Pacific Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.6.2 China Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.4.6.3 China Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.7.2 India Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.4.7.3 India Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.8.2 Japan Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.4.8.3 Japan Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.9.2 South Korea Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.4.9.3 South Korea Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.10.2 Singapore Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.4.10.3 Singapore Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.11.2 Australia Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.4.11.3 Australia Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.12 Rest of Asia-Pacific
10.4.12.1 Rest of Asia-Pacific Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia-Pacific Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia-Pacific Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa East Personalized Cancer Vaccine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.6.2 UAE Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.5.6.3 UAE Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.8.2 Qatar Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.5.8.3 Qatar Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9 1 South Africa Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.9 2 South Africa Personalized Cancer Vaccine Market Estimates and Forecasts By Technology (2021-2032) (USD Billion)
10.5.9 3 South Africa Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Personalized Cancer Vaccine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.6.4 Latin America Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.6.5 Latin America Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.6.6.2 Brazil Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.6.6.3 Brazil Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.6.7.2 Argentina Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.6.7.3 Argentina Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Personalized Cancer Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Personalized Cancer Vaccine Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Personalized Cancer Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12. Company Profiles
12.1 Gritstone Bio
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 Dendreon Pharmaceuticals
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 CureVac
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 NeoCura
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Innovent
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 Stemirna Therapeutics
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Elicio Therapeutics
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 Evaxion Biotech
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Imugene
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 Nouscom
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Type
Dendritic Cell
RNA-Based (mRNA)
Neoantigen-Based
Tumor-Associated Antigen (TAA) Vaccines
By Technology
Cell-based
mRNA PCV
Others
By Distribution Channel
Hospitals
Clinics
Research & Academic Institutes
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g., Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players